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Summary
Aggregation of the amyloid-b (Ab) peptide in the extra-
cellular space of the brain is central to Alzheimer’s dis-
ease pathogenesis. Ab aggregation is concentration
dependent and brain region specific. Utilizing in vivo
microdialysis concurrently with field potential record-
ings, we demonstrate that Ab levels in the brain inter-
stitial fluid are dynamically and directly influenced by
synaptic activity on a timescale of minutes to hours.
Using an acute brain slice model, we show that the
rapid effects of synaptic activity on Ab levels are pri-
marily related to synaptic vesicle exocytosis. These
results suggest that synaptic activity may modulate
a neurodegenerative disease process, in this case
by influencing Ab metabolism and ultimately region-
specific Ab deposition. The findings also have impor-
tant implications for treatment development.
Introduction
Amyloid-b (Ab) is a 38–43 amino acid peptide that is pro-
duced by proteolytic cleavage of the amyloid precursor
protein (APP). It is secreted by cells and is present in
a soluble form throughout life at highest concentrations
in the central nervous system. In the brain of individuals
with Alzheimer’s disease (AD), Ab aggregates and accu-
mulates in toxic forms as fibrils in neuritic plaques and
as soluble oligomers (Selkoe, 2001). Because the pro-
cess of aggregation and formation of these toxic struc-
tures within the extracellular space is concentration de-
pendent, the level of Abwithin the interstitial fluid (ISF) of
the brain is likely to be directly related to the probability
and onset of Ab aggregation (Meyer-Luehmann et al.,
2003). A variety of circumstantial evidence suggests
that, in humans, Ab levels and metabolism may be re-
lated in some way to neuronal activity. For example,
some patients with substantially elevated neuronal ac-
*Correspondence: holtzman@neuro.wustl.edutivity, as occurs in temporal lobe epilepsy, develop Ab-
containing plaques as early as 30 years of age (Gouras
et al., 1997; Mackenzie and Miller, 1994). Additionally,
the brain regions that develop the highest levels of Ab
plaques, such as parts of the frontal and parietal lobes
and posterior cingulate cortex, exhibit the highest base-
line metabolic activity at rest as measured by positron
emission tomography and functional magnetic reso-
nance imaging (Buckner et al., 2005; Gusnard et al.,
2001; Raichle et al., 2001). High metabolic activity gener-
ally reflects high neuronal and synaptic activity.
In addition to human data, there is evidence from
animal models and cell culture experiments that links
neuronal transport of APP, neuronal activity, and Abme-
tabolism. APP is axonally transported from entorhinal
cortex to the hippocampal formation via the perforant
pathway (Buxbaum et al., 1998); lesioning this pathway
in APP transgenic mice results in substantially less Ab
deposition within the hippocampus (Lazarov et al.,
2002; Sheng et al., 2002). Electrical depolarization in-
creases the release of soluble APP-a in rat hippocampal
brain slices (Nitsch et al., 1993). In studies of both ani-
mals and humans, activation of muscarinic M1 acetyl-
choline receptors has been reported to increase a-sec-
retase cleavage of APP and decrease Ab levels (Beach
et al., 2001; Hock et al., 2003). Utilizing organotypic slice
cultures from APP transgenic mouse brain, it was re-
cently shown that, after a 96 hr period, decreasing neu-
ronal activity reduces steady-state Ab levels in media,
whereas elevated activity increases Ab levels (Kamenetz
et al., 2003). Together, these data suggest that neuronal
and possibly synaptic activity may influence Abmetabo-
lism. We hypothesized that synaptic activity rapidly and
directly influences the level of ISF Ab, a precursor to Ab
aggregation and AD pathogenesis. To directly address
this hypothesis in vivo, we utilized a microdialysis tech-
nique in tandem with concurrent hippocampal electro-
physiological recording to assess whether there are
dynamic changes in ISF Ab levels in conjunction with dif-
fering levels of neuronal activity in awake, behaving mice.
Using an acute brain slice model, we further assessed the
cellular mechanisms, such as synaptic vesicle exocyto-
sis and APP processing, that underlie this phenomenon.
Results
Electrical Activity within the Perforant Pathway
Modulates ISF Ab Levels
Because Ab is generated and released from neurons into
the extracellular space, activity-related changes in Ab
levels would likely occur and be immediately reflected
in brain ISF. Microdialysis enables direct and frequent
assessment of ISF Ab in the setting of intact, complex
neural networks. To determine if neuronal activity di-
rectly influences ISF Ab levels in vivo, a recording elec-
trode was attached to a microdialysis probe to monitor
electroencephalographic (EEG) activity (extracellular field
potentials) and simultaneously measure ISF Ab levels in
the hippocampus of awake Tg2576 mice at 3–5 months
of age. These mice express a form of human APP that,
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914Figure 1. Modulating Neuronal Activity via the Perforant Pathway Alters ISF Ab Levels
(A) Representative traces of basal EEG activity (top) and epileptiform discharges during electrical stimulation of the perforant pathway (bottom) in
3- to 5-month-old Tg2576 mice. (B) When EEG activity was elevated, ISF Ab levels increased by 133.3%6 19.7% (p = 0.05; n = 5). (C) LY354740
(30 mM), a selective mGluR2/3 agonist, was administered into the hippocampus via reverse microdialysis to inhibit glutamate release from the
perforant pathway, causing ISF Ab levels to significantly decrease to 81.8% 6 4.9% (p = 0.0181) of baseline after 12 hr. This is consistent with
decreased neurotransmission from the perforant pathway leading to decreased ISF Ab levels. Data represent mean 6 SEM.in humans, results in early onset, familial AD and develop
Ab deposition in amyloid plaques beginning at about
8–9 months of age (Kawarabayashi et al., 2001). A sensi-
tive ELISA for Ab1–x enabled us to assess ISF Ab every
30 min for up to 24 hr within the same mouse (Cirrito
et al., 2003). Initially, we increased neuronal and synaptic
activity within the hippocampus by electrically stimulat-
ing the perforant pathway, the major afferent projection
from the entorhinal cortex to the hippocampus. With
continuous electrical stimulation, we created transient
epileptiform discharges within the hippocampus, result-
ing in increased hippocampal EEG activity (Figure 1A). A
microdialysis probe, with EEG recording electrodes at-
tached, was placed within the hippocampus to assess
ISF Ab levels during these electrical seizures. ISF Ab in-
creased within the first 30 min of stimulation and reached
130% of baseline within 1 hr (Figure 1B). This demon-
strates a direct relationship between increased neuronal
activity and increases in ISF Ab.
To determine if endogenous neural activity of the per-
forant pathway modulates ISF Ab levels within the hip-
pocampus, we infused LY354740, a selective metabo-
tropic glutamate receptor 2/3 (mGluR2/3) agonist into
the hippocampus via reverse microdialysis and moni-
tored ISF Ab levels. Within the hippocampus, mGluR2/3
is exclusively expressed on the presynaptic terminals of
the perforant pathway. When activated, mGluR2/3 de-
creases glutamate release into the dentate granule cell
neurons (Cartmell and Schoepp, 2000), thereby decreas-
ing neuronal activation. Infusion of LY354740 caused
a 18.2% 6 4.9% (p = 0.0181) decrease in ISF Ab levels
within the hippocampus, consistent with the hypothesis
that modulation of endogenous neuronal activity within
this pathway can affect hippocampal ISF Ab levels (Fig-
ure 1C). These data complement previous reports of le-
sions of the perforant pathway in APP transgenic mice
that caused decreased Ab deposition throughout the
hippocampus over months (Lazarov et al., 2002; Sheng
et al., 2002). Taken together, these studies suggest
that modulation of neuronal activity via the perforant
pathway can affect hippocampal ISF Ab levels and pos-
sibly subsequent Ab deposition as well.
Reduced Neuronal Activity Decreases ISF Ab Levels
Presynaptic modulation via mGluRs may cause rela-
tively small changes in overall hippocampal activity. Toaddress whether Ab levels can be reduced further by
strong depression of local activity, we administered
the sodium channel blocker tetrodotoxin (TTX) locally
throughreversemicrodialysiswhilesimultaneouslymon-
itoring EEG and local Ab concentration. TTX did not ob-
viously affect animal behavior during the experiment.
Baseline EEG activity and Ab levels were stable over
6 hr prior to TTX administration (Figures 2A–2C). Follow-
ing TTX infusion, however, EEG amplitude gradually de-
clined by approximately 70% compared to baseline over
6 hr and showed little to no activity by 12 hr (Figures 2A
and 2B). There was a concomitant, gradual 30% de-
crease in Ab levels by 6 hr that reached 60% of baseline
values by 15–16 hr after treatment with TTX (Figure 2C).
Ab subspecies, namely Ab40 and Ab42, decreased to the
same extent during TTX treatment (data not shown).
When EEG activity and Ab levels were compared at each
time point, there was a highly significant correlation be-
tween these measures (Figure 2D). To determine if the
effects of TTX on ISF Ab were reversible, we infused a
slightly lower dose of TTX for 4 hr and then continued
to follow both EEG amplitude and ISF Ab levels during
a 10 hr washout period. The 4 hr TTX infusion resulted
in a rapid decrease in EEG amplitude as well as a rapid
30% decrease in ISF Ab by 4 hr (Figures 2E and 2F). Dur-
ing the TTX washout, ISF Ab and EEG activity returned to
near baseline levels. Again, there was a significant corre-
lation between EEG amplitude and ISF Ab (Figure 2G),
further demonstrating a possible direct and causal rela-
tionship between neuronal activity and ISF Ab levels.
ISF Ab Is Directly Influenced by Synaptic Activity
TTX decreases neuronal and synaptic activity by block-
ing action potentials. To differentiate between the ef-
fects of action potentials versus synaptic activity, we
infused tetanus toxin into the brain immediately sur-
rounding the microdialysis probe to specifically inhibit
synaptic vesicle release. Once taken into axon termi-
nals, tetanus toxin cleaves VAMP-2 and inhibits fusion
and release of synaptic vesicles. While synaptic activity
is substantially decreased in the presence of tetanus
toxin, the overall level of neuronal activity and EEG am-
plitude does not change dramatically over 24 hr (Nilsen
et al., 2005). We found that 18 hr after tetanus toxin treat-
ment, EEG amplitude only decreased by 8% compared
to baseline (p = 0.0061) (Figure 3A). However, by 10 hr
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915Figure 2. Inhibiting Neuronal Activity De-
creases ISF Ab Levels
(A) Representative traces of basal hippocam-
pal EEG activity (top) and 16 hr following the
onset of continuous 5 mM TTX administration
via reverse microdialysis into the hippocam-
pus (bottom). EEG amplitude was substan-
tially decreased in the presence of TTX. (B)
EEG activity remained relatively constant
prior to TTX treatment but gradually declined
during the first 30 min of administration
and reached negligible levels by 16 hr (p <
0.0001). (C) As EEG activity declined, ISF
Ab1–x levels declined as well, reaching
70.4% 6 4.5% of baseline at 16 hr (p <
0.0001; n = 5). (D) When EEG activity and ISF
Ab levels at each time point within the same
mouse were compared, there was a highly
significant correlation (Pearson’s r = 0.6619;
p < 0.0001), further emphasizing the asso-
ciation between these measures. (E and F)
TTX (1 mM) was transiently administered for
4 hr, causing both EEG activity (E) and ISF
Ab levels (F) to decline; however, when TTX
was removed from the microdialysis perfu-
sion buffer, both of these measures returned
to baseline within 5 hr (n = 4). (G) Prior to
and during TTX washout, EEG activity and
Ab levels remained strongly correlated (Pear-
son’s r = 0.4935; p < 0.0001). Data represent
mean 6 SEM.following treatment, ISF Ab levels began to decrease,
and by 18 hr, Ab levels had decreased by 70% (Fig-
ure 3B). There was no evidence of cell death after teta-
nus toxin treatment as assessed by TUNEL staining(data not shown). Decreased ISF Ab in the absence of
a substantial change in EEG amplitude suggests that
changes in ISF Ab levels are specifically coupled to
synaptic activity. Inhibiting synaptic transmission withFigure 3. Synaptic Activity Regulates ISF Ab Levels
Tetanus toxin (0.2 mg) was injected directly into the hippocampus surrounding the microdialysis probe to inhibit synaptic vesicle release. By 18 hr
following treatment, EEG activity only declined by 8.2%6 1.2% (p = 0.0061) (A), whereas ISF Ab levels declined by 61.8%6 5.3% (B) compared
to baseline (p = 0.0003; n = 4). Data represent mean 6 SEM.
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916Figure 4. Depressed Synaptic Activity Alters
APP Processing, Not ISF Ab Elimination
(A) ISF Ab half-life was assessed in Tg2576
mice pretreated with vehicle or 1 mM TTX.
After 8 hr of TTX treatment, when Ab levels
reached a new steady-state level, animals
were injected with 3 mg/kg of LY411575, a po-
tent g-secretase inhibitor. ISF Ab levels were
sampled at 30 min intervals following treat-
ment. After 4 hr, ISF Ab levels were less
than 10% of the new baseline of each group
(n = 4–5 per group). (B) The elimination of
ISF Ab followed first-order kinetics, and the
half-life of Ab was nearly identical in mice
treated with vehicle and TTX: 0.93 6 0.085
hr and 1.06 6 0.073 hr, respectively (n = 4–5
per group). To determine if TTX altered ex-
pression of the Ab-degrading enzyme nepri-
lysin, Tg2576 mice were treated by reverse
microdialysis with 1 mM TTX for 16 hr, fol-
lowed by microdissection of the treated
hippocampus. Each hippocampus was pro-
cessed for Western blot analysis, and the
level of neprilysin was assessed (n = 7 per
group). Each band was normalized to the
amount of tubulin in each lane. (C) The level
of neprilysin was the same in vehicle- and
TTX-treated mice. (D) Representative lanes
from Western blot. To determine if APP pro-
cessing was altered in the presence of TTX,
the same tissues were also assessed for the
levels of full-length APP (FL-APP), a-CTF,
and b-CTF (n = 7 per group). (E) FL-APP and
b-CTF did not change after TTX treatment;
however, there was a significant increase in
a-CTF (p = 0.007), suggesting that inhibition
of neuronal activity alters APP processing.
(F) Representative lanes from Western blot.
Data represent mean 6 SEM.tetanus toxin had a greater effect on ISF Ab levels than
did TTX. One possible explanation is the type of activity
that remains in the presence of each agent; spontane-
ous synaptic vesicle release and miniature synaptic po-
tentials still occur in the presence of TTX, whereas nearly
all synaptic transmission is inhibited with tetanus toxin
(Verderio et al., 1999). This suggests that even low levels
of synaptic activity can contribute to ISF Ab levels.
Elimination of ISF Ab Is Not Altered
in the Presence of TTX
Changes in Ab levels that are due to synaptic activity
could be mediated by altered Ab clearance from ISF or
altered Ab production/release. To test these possible
contributing mechanisms, we assessed both ISF Abhalf-
life and APP processing in mice treated with TTX. To de-
termine whether Ab transport or clearance was involved,
we administered either vehicle or TTX locally into the hip-
pocampus similar to previous experiments. TTX treat-
ment at a lower dose resulted in a steady-state 20% de-
crease in ISF Ab (Figure 4A). When a new steady-state
level of Ab was established, both groups were then ad-
ministered a potent g-secretase inhibitor (LY411575)
which rapidly crosses the blood-brain barrier and effec-
tively inhibits g-secretase activity within minutes. This
inhibitor causes a decrease in brain Ab levels with a con-
comitant increase in APP a- and b-C-terminal fragments
(CTF) (Cirrito et al., 2003; Lanz et al., 2004). Similarly to
previous reports (Cirrito et al., 2003; DeMattos et al.,2004), LY411575 resulted in a rapid decrease in ISF Ab
levels such that, by 4 hr, Ab levels were less than 10%
of baseline (Figure 4A). The elimination half-life of ISF
Ab was approximately 1 hr in both TTX- versus vehicle-
treated mice (Figure 4B). The half-life of ISF Ab in
Tg2576 mice is substantially faster than that previously
reported in PDAPP transgenic mice (Cirrito et al., 2003),
which is likely due to the higher ratio of Ab40:Ab42 in
Tg2576 mice (Fryer et al., 2003). That the half-life remains
the same during depressed neuronal activity suggests
that TTX does not affect clearance of Ab from the ISF.
Previous reports have shown that environmental en-
richment of APP transgenic mice may influence brain
Ab levels by altering expression of neprilysin, an Ab-
degrading enzyme (Lazarov et al., 2005). We assessed
neprilysin levels in the hippocampus of Tg2576 mice
that were treated with vehicle or 1 mM TTX for 16 hr via
reverse microdialysis. The treated hippocampus was
microdissected and processed for Western blot analy-
sis. Neprilysin levels did not change in response to TTX
administration (Figures 5C and 5D), further suggesting
that Ab elimination is not altered in response to reduced
neuronal activity.
Neuronal Activity Influences APP Processing In Vivo
To determine if synaptic activity influences APP pro-
cessing, we assessed APP-CTF following subacute
treatment with TTX into the hippocampus. Ab produc-
tion from APP first requires b- followed by g-secretase
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917cleavage, producing b- and g-CTF respectively, whereas
cleavage by a-secretase produces a-CTF and precludes
Ab formation. TTX or vehicle was infused for 16 hr by
reverse microdialysis into the hippocampus of Tg2576
mice followed by assessment of tissue levels of a- and
b-CTF as markers of APP processing. TTX treatment
did not alter the level of full-length APP within the hippo-
campus. However, there was a significant 13% increase
in a-CTF with no appreciable difference in b-CTF (Fig-
ures 4C and 4D). While this suggests that TTX may affect
ISF Ab levels in part via increasing a-secretase cleavage
of APP, the change in APP processing was much less
than the decrease in ISF Ab levels seen at the same time
point. Thus, this prompted further experiments to deter-
mine whether another process might also be linked to
how synaptic activity modulates extracellular Ab levels.
Changes in Extracellular Ab Levels Are Modulated
by Synaptic Vesicle Exocytosis
Because electrical activity and synaptic transmission
have several effects on cellular processes, we sought
to further define the mechanisms by which synaptic ac-
tivity dynamically regulates extracellular Ab levels. To
this end, we developed an in vitro acute brain slice model
that is amenable to complex pharmacological manipula-
tions. Acute brain slices were prepared from 4- to 5-
week-old Tg2576 mice. After the brain slices were pre-
pared, they were permitted to recover for 3 hr in media
before being transferred to fresh media for experimental
conditions. After a 12 hr incubation, extracellular Ab1–x
levels in media were 110.6 6 4.4 pg/ml (mean 6 SEM;
n = 16). To determine if the brain slices actively degraded
Ab within the media, exogenous human Ab40 was added
to slice chambers that contained either wild-type mouse
slices or media alone. Over 12 hr, Ab40 levels declined
10% from initial levels (Figure 5A); however, the de-
crease in Ab levels was identical whether tissue was
present within the chamber or not, suggesting that the
small loss of Ab was due to nonspecific binding to the
chamber and not to active elimination by the brain slice.
Human Ab42 levels also declined to the same extent
whether wild-type tissue was present within the cham-
ber or not (data not shown). Next, we treated brain slices
from Tg2576 mice with a range of doses of LY411575,
a g-secretase inhibitor, which lowered Ab levels in media
by up to 66% over 12 hr (Figure 5B). Similar to our find-
ings in vivo, slices treated with agents that decrease and
increase neuronal activity can modulate Ab levels in
media over 6–12 hr (Figure 5C). TTX caused a 29% (p <
0.01) decrease, whereas 25 mM potassium chloride
caused a 27% (p < 0.01) increase in extracellular Ab
levels.
Given that our slice preparation reliably replicated
several of the in vivo findings, we next sought to define
which cellular processes that are related to synaptic
activity regulate extracellular Ab levels. In particular,
we assessed the effects of synaptic vesicle exocytosis
and the effects of neuronal activity on cellular processes
such as APP cleavage. We treated brain slices from
Tg2576 mice with either a-latrotoxin, a cocktail of syn-
aptic activity inhibitors, or a-latrotoxin and the inhibi-
tor cocktail together. a-latrotoxin binds to neurexin re-
ceptors on the presynaptic plasma membrane, which
causes considerable synaptic vesicle release that isindependent of presynaptic depolarization or activity
(Sudhof, 2001). The inhibitor cocktail included TTX,
NBQX, and APV in order to dramatically decrease volt-
age-gated and postsynaptic activity within the slice, as
well as limit excitotoxicity that could potentially occur
from a massive release of glutamate within the slice.
This paradigm enabled us to separate the effects of syn-
aptic vesicle exocytosis from those of neuronal activity.
a-latrotoxin alone caused a 35% (p < 0.0001) increase in
media Ab levels, whereas the inhibitor cocktail caused a
18% (p = 0.0036) decrease in media Ab levels over 2 hr
compared to untreated slices (Figure 5D). Interestingly,
compared to slices treated with the activity inhibitor
cocktail alone, Ab levels increased 38% (p < 0.0001)
when synaptic vesicles were released in the presence
of activity blockade (a-latrotoxin and inhibitor cocktail
cotreatment). This suggests that synaptic vesicle exo-
cytosis alone can drive changes in Ab levels that are in-
dependent of neuronal activity. Interestingly, media Ab
levels from slices cotreated with a-latrotoxin and inhibi-
tors were significantly lower than those from slices trea-
ted with a-latrotoxin alone, suggesting that neuronal ac-
tivity may modulate Ab levels to some extent, but that
this change is independent of synaptic vesicle exocyto-
sis. LDH levels in media were the same in all treatment
conditions, suggesting that there was no difference in
cell death between the groups (data not shown).
To determine whether synaptic vesicle exocytosis and
concomitant changes in Ab levels were due to effects on
APP processing, we assessed levels of APP a-CTF and
b-CTF in tissue homogenates of these slices at 2 hr post-
treatment, the time point at which there was a 38% in-
crease in Ab levels. APP-CTF levels were not changed
by treatment with latrotoxin, activity inhibitors, or the
combination (Figures 5E and 5F), indicating that the
large, acute increase in media Ab levels is unlikely to be
mediated by changes in APP cleavage to a substantial
degree. These data suggest that acute changes in extra-
cellular Ab levels that are modified by synaptic activity
are directly modulated by processes related to synaptic
vesicle release. Although APP processing might be af-
fected by activity under certain conditions (Figures 4E
and 4F), processing effects are not necessary for rapid,
activity-driven changes in Ab levels.
Discussion
The concentration of Ab in the extracellular space of the
brain is critical in ultimately determining whether it will
aggregate into toxic species. Thus, the mechanisms
that regulate Ab levels are important in the pathogenesis
and treatment of AD. Our data strongly suggest that
synaptic activity rapidly and dynamically regulates ISF
Ab levels in vivo. The relationship between synaptic ac-
tivity and extracellular Ab levels appears to be related to
synaptic vesicle release; extracellular Ab levels are in-
creased when synaptic vesicles undergo exocytosis
even in the absence of neuronal activity. This suggests
that the rapid effects of synaptic activity on Ab are medi-
ated at the presynaptic side of the synaptic cleft. Addi-
tionally, in the presence of tetanus toxin, ISF Ab levels
decline 90% compared to basal levels in vivo, demon-
strating a dramatic effect of vesicle release on extracel-
lular Ab levels.
Neuron
918Figure 5. Extracellular Ab Levels Are Directly Linked to Synaptic Vesicle Exocytosis
Acute brain slices were made from 4- to 5-week-old wild-type (B6/SJL) or Tg2576 mice. (A) To determine if extracellular Ab is actively eliminated
by the slice, 300 pg/ml of exogenous human Ab was added to culture chambers containing either no tissue or brain slices from wild-type mice.
Over 12 hr, Ab levels declined by 11.0%6 3.0% compared to the initial collection regardless of whether tissue was present in the chamber or not
(n = 5 per group). (B) Brain slices from Tg2576 mice were incubated with several concentrations of LY411575, a g-secretase inhibitor. At 10 nM
and 100 nM, Ab levels decreased significantly by 53.1% 6 6.6% and 66.4% 6 3.7%, respectively, as compared to untreated slices (n = 6 per
group). (C) Slices from Tg2576 mice were stimulated with 25 mM KCl or inhibited with 100 nM TTX for 12 hr, resulting in 27.3% 6 4.2% more
and 24.2% 6 6.9% less extracellular Ab, respectively, than untreated slices over 12 hr (n = 6 per group). (D) To determine the effect of synaptic
vesicle exocytosis on extracellular Ab levels in the absence of synaptic activity, Tg2576 brain slices were cultured for 2 hr in the presence of
0.5 nM a-latrotoxin and/or a cocktail of activity inhibitors including 100 nM TTX, 10 mM NBQX, and 50 mM APV. a-latrotoxin alone caused
a 35%6 6.9% increase in Ab levels, whereas the inhibitor cocktail lowered Ab levels by 18.0%6 4.1% compared to untreated slices. a-latrotoxin
plus the inhibitor cocktail resulted in 13.3% more extracellular Ab as compared to untreated slices and 38.3%6 6.2% more Ab compared to the
inhibitor cocktail alone (n = 12–15 per group). At the conclusion of each experiment, brain slices were washed with PBS and processed for West-
ern blot analysis of APP-CTF. (E) Neither the level of a-CTF nor the level of b-CTF changed over the 2 hr culture period. (F) Representative lanes
from Western blot. Data represent mean 6 SEM.Electron micrograph and biochemical studies have lo-
calized APP to axonal vesicles that are distinct from syn-
aptic vesicles (Ikin et al., 1996; Marquez-Sterling et al.,
1997). APP is cointernalized from the plasma membrane
with synaptic vesicle integral membrane proteins such
as synaptophysin and synaptotagmin, then sorted away
from those proteins and incorporated into distinct ves-
icles (Marquez-Sterling et al., 1997), suggesting that syn-
aptic vesicle membrane recycling and APP endocytosis
are linked. APP endocytosis is directly linked to Ab gen-
eration and release (Koo and Squazzo, 1994). Previous
studies have shown that increasing the rate of synaptic
vesicle membrane recycling can increase the rate of APP
cleavage (Lyckman et al., 1998). While synaptic vesicle
exocytosis can rapidly modulate extracellular Ab levels,
it may actually be an associated event, such as mem-
brane recycling or another process, that is directly re-
sponsible for modulating extracellular Ab levels.Synaptic vesicle release appears to be the primary
mediator of rapid changes in extracellular Ab levels that
are linked with synaptic activity. Over longer periods, it
appears that an independent, activity-related process
may also modulate Ab levels, likely via APP processing.
While our in vivo studies suggest a possible role of neu-
ronal activity on a-secretase cleavage, we did not find a
similar change in our acute brain slice model when neu-
ronal activity was inhibited. Our slices, however, were
only treated for 2 hr due to the rapid action ofa-latrotoxin,
making it possible that later time points could have
shown differences in APP processing. Numerous rodent
and human studies have demonstrated that activation of
muscarinic cholinergic receptors can alter a-secretase
cleavage of APP via changes in protein kinase C activity,
thereby affecting brain and CSF Ab levels (Beach et al.,
2001; Canet-Aviles et al., 2002; Hock et al., 2003; Nitsch
et al., 2000). Kamentez and colleagues demonstrated in
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919slice culture that increasing neuronal activity with picro-
toxin and calcium chloride increases b-secretase cleav-
age of APP (Kamenetz et al., 2003). The discrepancy be-
tween neuronal activity affecting a- versus b-secretase
cleavage of APP may be related to the particular models
and agents used or the time course that each treatment
was assessed. Thus, under specific conditions, such as
mAChR activation, neuronal activity can modulate Ab
generation by affecting APP processing. However, this
process appears to be secondary and distinct from rapid
changes in extracellular Ab levels that are due to synaptic
vesicle exocytosis and are independent of changes in
APP processing.
In addition to synaptic activity influencing Ab levels,
recent studies have shown that Ab can modulate activa-
tion of nicotinic acetylcholine receptors (Wu et al., 2004)
as well as glutamatergic synapses (Kamenetz et al.,
2003). Taken together with data presented here, it is
conceivable that a feedback loop exists between synap-
tic activity and ISF Ab levels; that activity-dependent
changes in ISF Ab levels then affect subsequent activa-
tion of the same, or nearby, cells. The presence and
function of such a loop in vivo, or its consequence in
the presence of aggregated Ab or AD, remains unknown.
Neuronal activity levels likely decreases with AD pro-
gression. If so, why does Ab plaque formation continue?
Although initial Ab plaque deposition is concentration
dependent, the threshold for fibril growth is likely
much lower in the presence of existing plaques, which
can act as a nidus, or seed, for plaque formation (Kane
et al., 2000). Thus, despite lower activity-driven Ab levels
that may occur following the development of plaques,
Ab accumulation could continue. Interestingly, the level
of ISF Ab in 12-month-old PDAPP mice that contain Ab
plaques is somewhat lower than that in 3-month-old,
plaque-free mice (Cirrito et al., 2003), even though the
older mice will continue to develop Ab plaques. To better
understand the relationship between ISF Ab and Ab de-
position, it will be useful to know the level of ISF Ab im-
mediately prior to initial plaque formation and whether
increasing levels of ISF Ab are associated with earlier
onset of plaque deposition.
The fact that synaptic activity directly regulates Ab
levels in vivo may explain several AD- and Ab-related
phenomena. First, despite the ubiquitous expression of
APP in virtually all brain regions, Ab deposition in both
humans and animal models occurs in specific brain re-
gions in a similar pattern, suggesting that activity within
particular neuronal networks is involved. Second, that
physical and cognitive activity can alter plaque burden
later in life may be related to changes in synaptic activ-
ity. A recent paper by Buckner and colleagues demon-
strates that areas of the human brain that develop the
most Ab plaques also have the highest basal rates of
metabolic and neural activity, as measured by PET and
fMRI, when an individual is not performing a specific
mental task, the so-called ‘‘default state’’ (Buckner
et al., 2005; Raichle et al., 2001). The high level of activity
in these areas may make them particularly susceptible
to Ab deposition because of the activity/Ab relationship.
Recent evidence in APP transgenic mice shows that
physical and cognitive enrichment results in altered Ab
plaque burden (Adlard and Cotman, 2004; Jankowsky
et al., 2003, 2005; Lazarov et al., 2005). Environmentalenrichment that results in decreased or increased Ab
deposition in animals may cause these effects through
modulation of synaptic activity. If so, how might this oc-
cur? One hypothesis is that enrichment may increase
overall synaptic activity in some brain regions and de-
crease it in others, depending on the environmental al-
teration. For example, certain memory tasks in humans
simultaneously increase and decrease activity within
different brain areas (Buckner and Koutstaal, 1998). In-
creased activity might result in increased susceptibility
to Ab deposition if the activated neural circuits contain
high levels of human APP expression, thereby increas-
ing Ab release from those pathways. Conversely, if syn-
aptic activity decreases in a brain area that is normally
vulnerable to Ab pathology, then there may be reduced
Ab deposition as a consequence of enrichment. This hy-
pothesis can be tested in future studies.
These findings are consistent with the possibility that
physical and environmental changes resulting in altered
neuronal/synaptic activity throughout life can modulate
the amount of Ab that accumulates in plaques in a re-
gion-dependent manner. That synaptic activity and Ab
levels are directly linked in vivo may have important
treatment implications. Drugs used to treat various neu-
ropsychiatric disorders, such as depression or anxiety,
among many others, directly influence neurotransmit-
ters, and their receptors, thereby altering synaptic activ-
ity. Thus, it is likely that these drugs might influence Ab
levels within specific neuronal networks as well (Phiel
et al., 2003). If so, such drugs could potentially influence
risk or progression of AD. Understanding the effects of
drugs on ISF Ab may enable the design of ways to de-
crease soluble Ab levels, including synaptotoxic Ab
oligomers, in specific brain regions. Defining the rela-
tionship between normal brain function and the metab-
olism of a key protein involved in a neurodegenerative
disease may provide new clues into the factors that reg-
ulate the biology of AD as well as other disorders of the
nervous system.
Experimental Procedures
Animals
All experimental procedures involving animals were performed in
accordance with guidelines established by the Animal Studies Com-
mittee at Washington University. We bred Tg2576+/2 hemizygous
mice (a generous gift from Dr. K. Ashe, University of Minnesota) to
C57Bl6/SJL mice (Taconic Farms, Germantown, NY), then aged the
Tg2576+/2 offspring to 3–5 months for use in experiments. Animals
were screened for the Tg2576 transgene by PCR from tail DNA.
ELISA
ISF Ab values reported represent Ab1–x and were analyzed as de-
scribed (Cirrito et al., 2003). Briefly, Ab1–x was assessed using
a sandwich ELISA; a central domain, mouse monoclonal antibody
(m266) was used to capture, and a biotinylated N-terminal, human
Ab-specific antibody (m3D6) was used to detect, followed by strep-
tavidin-poly-HRP-20 (RDI, Flanders, NJ). The assay was developed
using Slow ELISA TMB (Sigma, St. Louis, MO) and read on a Bio-Tek
FL-600 plate reader (Winooski, Vermont) at 650 nm.
In Vivo Microdialysis
In vivo microdialysis to assess brain ISF Ab1–x in the hippocampus of
awake, freely moving Tg2576 mice was performed in a manner sim-
ilar to that previously described (Cirrito et al., 2003). This technique
samples soluble molecules within the extracellular fluid that are
smaller than 38 kDa, the molecular weight cutoff of the probe
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changeable Ab or eAb’’ (Cirrito et al., 2003).
Under isoflurane volatile anesthetic, guide cannulae (BR-style,
Bioanalytical Systems, Indianapolis, IN) were cemented into the left
hippocampus (bregma 23.1 mm, 2.4 mm lateral to midline, and
0.6 mm below dura at a 12º angle). Two millimeter microdialysis
probes were inserted through the guides so the membrane was con-
tained entirely within the hippocampus (BR-2, 38 kDa MWCO mem-
brane, Bioanalytical Systems). Microdialysis perfusion buffer was
artificial CSF containing 0.15% bovine serum albumin that was
filtered through a 0.1 mM membrane. Flow rate was a constant
1.5 ml/min. Samples were collected every 30–60 min with a refriger-
ated fraction collector into polypropylene tubes and assessed for
Ab1–x by ELISA at the completion of each experiment. Basal levels
of ISF Ab were defined as the mean concentration of Ab from hours
5–10 after probe insertion. Following each experiment, animals were
sacrificed, and probe placement was verified histologically with
cresyl violet staining.
EEG Recording
To record EEG activity, bipolar recording electrodes (Teflon-coated,
stainless steel wire, 0.0055 inches coated OD, A-M Systems, Carls-
borg, WA) were attached to the shaft of the microdialysis guide can-
nula with Elmer’s Super-Fast Epoxy Resin (Elmer’s, Columbus, OH).
Electrodes extended w1 mm from the tip of the guide, so that the
electrode tip was located at the center of the 2 mm microdialysis
membrane. EEG activity was assessed using a P511K A.C. Pre-am-
plifier (Grass Instruments, Quincy, MA), digitized with a DigiData
1322A Data Acquisition System (Axon Instruments, Union City,
CA), and recorded digitally using pClamp 9.2 (Axon Instruments).
Perforant Pathway Stimulation
Microdialysis was performed as described previously; however, im-
plant coordinates were altered to coincide with optimized perforant
pathway stimulation. The stimulating electrode (model SNE-200X-
35, Rhodes Medical, Summerland, CA) was implanted at bregma
24.3 mm, 2.9 mm lateral to midline, at w1.2–1.6 mm below dura.
Precise depth of the stimulating electrode was optimized based
on evoked waveform pattern. To optimize the stimulation electrode,
a recording electrode was temporarily placed within the dentate
granule cell layer (coordinates bregma 22.5 mm, 1.5 mm lateral to
midline, atw1.5–1.9 mm below dura). After placement of the stimu-
lating electrode was optimized, the recording electrode was re-
moved, and the microdialysis guide cannula, with EEG recording
electrodes attached, was inserted at coordinates bregma22.5 mm,
0.3 mm lateral to midline, 1.5 mm below dura at a 42º angle. This pro-
cedure permitted optimal placement of the stimulation electrode
within the perforant pathway that contained axons projecting near
to the microdialysis membrane. Two bone screws were used; one
had a grounding wire attached. The cannula/electrode assembly was
then cemented to the skull. The DigiData 1322A and stimulus isolator
(WPI, New Haven, CT) was used to deliver evoked potentials during
electrode placement.
To evoke population spikes and epileptiform discharges in awake
mice, the stimulation paradigm was based on a previously described
procedure (Sloviter et al., 1996). A Master-8 stimulator (A.M.P.I,
Herts, UK) with stimulus isolator (WPI) was used to deliver pulses
at 20 V, 0.1 ms duration. EEG activity was measured during stimula-
tion as described previously. Stimulation increased stepwise from
1 Hz paired pulses with a 40 ms interval to 1 Hz paired pulses with
10 s of 20 Hz trains per minute. Paired-pulse interval was gradually
increased from 40 to 100 ms, at 20 ms increments for 5 min each, fol-
lowed by continuous 3 Hz paired pulses with a 40 ms interval with
10–30 s of 20 Hz trains per minute. In rare cases, the length of trains
was reduced if the animal had convulsions that lasted longer than
3 min.
Drug Treatment
All agents, except as noted, were purchased from Sigma-Aldrich
(St. Louis, MO). a-latrotoxin and APV were purchased from Alomone
Labs (Jerusalem, Israel) and Tocris (Ellisville, MO), respectively.
LY354740 and LY411575 were gifts from Eli Lilly and Co. In vivo
agents were administered intraperitoneally or directly to the brain
by reverse microdialysis or by direct injection. For reverse microdial-ysis, drugs were diluted in the microdialysis perfusion buffer. For
larger molecules that required direct injection, special microdialysis
probes containing a separate injection port at the tip were used to
permit drug treatment at the precise location of dialysis (IBR-style
probes, Bioanalytical Systems).
Ab Elimination Half-Life
ISF Ab half-life was determined as described (Cirrito et al., 2003).
Microdialysis probes were inserted as described previously. Basal
levels of ISF Ab were established from hours 5–10, followed by ad-
ministration of 1 mM TTX or vehicle via reverse microdialysis for
the remainder of the experiment. Eight hours after treatment began,
LY411575, a potent, blood-brain barrier-permeable g-secretase in-
hibitor (Eli Lilly and Co., Indianapolis, IN), was administered sub-
cutaneously at 3 mg/kg body weight in corn oil. Samples were col-
lected every 30 min for an additional 8 hr, then assessed for Ab1–x
by ELISA.
Western Blotting
Western blots were performed as described (Cirrito et al., 2003).
Briefly, hippocampal tissue from 3- to 4-month-old Tg2576 mice
was homogenized in RIPA buffer containing the following: 150 mM
NaCl, 50 mM Tris (pH 7.4), 0.5% deoxycholic acid, 0.1% SDS, 1% Tri-
ton X-100, 2.5 mM EDTA, and protease inhibitors. Western blotting
for full-length APP, APP-CTF, and neprilysin was performed using
10% Bis-Tris NuPAGE gels (Invitrogen, Carlsbad, CA) under reduc-
ing conditions with 5 mg of protein loaded per lane. Nitrocellulose
blots were probed with rabbit-anti-APP directed against the C termi-
nus of APP (Invitrogen) or rabbit anti-neprilysin (Santa Cruz Biotech-
nology, Santa Cruz, CA), followed by goat anti-rabbit conjugated to
peroxidase (BioRad, Hercules, CA). Gels were stripped and re-
probed with rabbit anti-tubulin (Sigma, St. Louis, MO) as a loading
control protein. Bands were detected with Lumigen-TMA6 (Amer-
sham, Piscataway, NJ) and captured digitally using the Kodak Im-
ageStation 440CF. Densitometry was performed using the Kodak
1D Image Analysis software, and each band was normalized to tubu-
lin signal in each lane.
Acute Brain Slices
Acute brain slices were prepared from 4- to 5-week-old Tg2576+/2
mice on a B6/SJL background or from wild-type littermates. Animals
were anesthetized with isoflurane, and brains were rapidly removed
into a chilled sucrose slicing solution consisting of the following:
87 mM NaCl, 25 mM NaHCO3, 2.5 mM KCl, 1.25 mM NaH2PO4,
25 mM glucose, 75 mM sucrose, 0.5 mM kynurenic acid, 0.5 mM
CaCl2, 3 mM MgCl2 and bubbled with 95% O2/5% CO2. The cerebel-
lum was removed, and the brain was super-glued dorsal side down
into the vibratome tray and covered with chilled sucrose slicing so-
lution. A sagittal cut was made along the midline with a straight razor
blade to produce horizontal hemibrain slices. Horizontal slices (300
mm) were prepared in order to create acute brain slices containing
comparable surface areas of the major APP-producing regions in
these mice, namely the hippocampus and cortex. After being cut,
each slice was immediately transferred to a room temperature bath
solution containing the following: 125 mM NaCl, 25 mM NaHCO3,
3 mM myo-inositol, 2 mM sodium pyruvate, 2.5 mM KCl, 1.25 mM
NaH2PO4, 0.4 mM ascorbic acid, 10 mM glucose, 2 mM CaCl2,
1 mM MgCl2 that was bubbled with 95% O2/5% CO2. When all slices
were made, tissue was transferred from bath solution to incubation
chambers containing 1 hemislice and 2 ml slice medium (25% inac-
tivated horse serum, 0.53 MEM, 0.253 Hank’s BSS, 5 mM Tris-
Base, 26 mM sodium bicarbonate, and penicillin/streptomycin)
with ambient 5% CO2 in a 35ºC tissue culture incubator. Slices re-
covered in incubation chambers for 3 hr, then were transferred to
fresh media for experimental conditions, which lasted from 2 to
12 hr. Drugs were added to the media when tissue was transferred
to fresh media with the exception of neuronal activity blockers,
such as TTX, NBQX, or APV, which were also added during the re-
covery phase to ensure activity was maximally reduced.
Incubation chambers were constructed of a polycarbonate dish
with the top 8–10 mm of a 50 ml polypropylene conical tube attached
with araldite epoxy (Electron Microscopy Science, Port Washington,
PA). Tissue was incubated on a cell strainer insert with a 70 mm pore
size membrane (BD Biosciences, Bedford, MA). Slice medium was
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of tissue to pre-aerate the media, as well as block nonspecific bind-
ing sites of the chamber.
Each experiment consisted of 12 to 14 separate brain slices, with
each condition run at least in triplicate. Ab levels in the media were
determined by ELISA specific for human Ab1–x, and each sample
was normalized to the mean Ab concentration of the untreated slices
within that experiment. Final analysis consisted of normalized Ab
levels from 3 to 6 replicate experiments. To assess APP-CTF, brain
slices were washed twice with chilled PBS and frozen at 280ºC for
biochemical analysis. Slices were lysed by sonication in 203 volume
of RIPA buffer.
Statistical Analysis
Data in figures represent mean 6 SEM. All statistical analysis was
performed using Prism version 4.02 for Windows (GraphPad, San
Diego). Statistical analysis was performed using a nonparametric
Mann-Whitney t test and was accepted as significant if p % 0.05.
EEG amplitude standard deviation was assessed for 30–60 min
epochs with pClamp 9.2 software. Comparisons between multiple
groups in acute brain slice experiments was performed using one-
way ANOVA with Bonferroni post hoc test.
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